![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
DOLUTEGRAVIR-BASED ART IS SUPERIOR TO
NNRTI/PI-BASED ART IN CHILDREN AND ADOLESCENTS
|
|
|
Anna Turkova, for the ODYSSEY/PENTA-20 Trial Team
MRC Clinical Trial Unit at UCL, London, UK
ODYSSEY is an international multi-centre randomised non- inferiority trial evaluating dolutegravir (DTG) + 2NRTIs versus standard-of-care (SOC) in children starting first- or second-line ART.
![0310211](../images/031021/031021-6/0310211.gif)
![0310212](../images/031021/031021-6/0310212.gif)
![0310213](../images/031021/031021-6/0310213.gif)
![0310214](../images/031021/031021-6/0310214.gif)
![0310215](../images/031021/031021-6/0310215.gif)
![0310216](../images/031021/031021-6/0310216.gif)
![0310217](../images/031021/031021-6/0310217.gif)
![0310218](../images/031021/031021-6/0310218.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|